Navigation Links
Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
Date:7/22/2010

MOUNTAIN VIEW, Calif., July 22 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Joseph L. Turner has been appointed to its Board of Directors.  Mr. Turner was also appointed to serve as the Chair of the Board's Audit and Ethics Committee.

Mr. Turner has over 25 years of experience as a financial manager in the biotech and pharmaceutical industries, including 14 years as a Chief Financial Officer.  Most recently, Mr. Turner served as Chief Financial Officer at Myogen, Inc., a publicly-traded biopharmaceutical company, which he joined in 1999 and served until it was acquired by Gilead Sciences in 2006.  Previously, he was Chief Financial Officer at Centaur Pharmaceuticals, Inc. and Vice President, Finance and Administration at Cortech, Inc.  Mr. Turner began his career at Eli Lilly and Company, where he served for 12 years in various financial positions and functions.  

Mr. Turner currently serves on the Board of Directors and Audit Committee of QLT Inc., a publicly-traded pharmaceutical company, Sequel Pharmaceuticals, Inc., a privately-held biotechnology company, and Kythera Biopharmaceuticals, Inc., a privately-held pharmaceutical company.  Since 2009, Mr. Turner has also served on the Board of Managers of Swarthmore College and in June 2010, he was appointed to its Finance Committee, Academic Affairs Committee and Student Affairs Committee.  Previously, Mr. Turner served on the Board and Audit Committee of SGX Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, and on the Board and as Chair of the Audit Committee of NovaCardia, Inc., a pri
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
2. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
3. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
4. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
5. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
6. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
7. Alexza Pharmaceuticals Files Shelf Registration Statement
8. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
9. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
10. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
11. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2011 , ReportsnReports adds market ... & Forecasts to 2017 for Greece, Hungary & ... provide value (USD million), volume (units) and average ... within 10 market categories - Cardiac Assist Devices, ...
... Mass., Sept. 20, 2011 Intrinsic Therapeutics, a ... address the spine market,s many unmet needs, today ... and Chief Executive Officer. Mr. Hagan brings over ... field with significant expertise in product development, commercialization ...
Cached Medicine Technology:ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 2ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 3ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 4Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO 2
(Date:7/10/2014)... health-conscious people around the globe have taken antioxidant supplements ... one of the paths to good health and a ... antioxidant supplements have repeatedly dashed the hopes of consumers ... Virtually all such trials have failed to show ... several trials antioxidant supplementation has been linked with increased ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... reveal that sudden, acute episodes of low back pain ... humidity, air pressure, wind direction and precipitation. Findings published ... of the American College of Rheumatology (ACR), indicate that ... higher wind speed or wind gusts, but was not ... Organization (WHO) nearly everyone experiences low back pain at ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... price of efavirenz 600mg tablets (Stocrin) for developing countries that ... ,It is the second price cut in a ... efavirenz cheaper than a generic import in Thailand, where a ... from India. ,For least developed countries and ...
... case management that takes a patient’s specific culture ... decrease the incidence of diabetes-related complications over the ... ,"Better management results in reduced long-term complications, such ... lead researcher Todd Gilmer, Ph.D. ,The ...
... Japanese researchers have successfully developed artificial teeth that they ... eventually help with similar procedures in humans. ... a single cell implanted into the mouths of adult ... in humans, reported the online edition of Australia's The ...
... Insufficient sleep at night could have an adverse effect ... that shows// how important the evening slumber is for ... University Of Colorado School Of Medicine and other researchers ... out by students attending middle school or high school, ...
... not worry about getting their bodies back into shape immediately, ... body has enough to do after a baby arrives," said ... ,New mothers also have to reckon with fatigue ... Pfarrer of the insurer DAK in Hamburg. And nursing a ...
... have literally found the needle in the haystack as ... help to discover hitherto unknown genetic material that causes ... in the prevention and treatment of autism has been ... all part of an international team from 8 countries ...
Cached Medicine News:Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2Health News:Sleep Disturbances Could Affect Performances in School 2Health News:New Gene Linked to Autism Discovered 2
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
Medicine Products: